The Economic Impact of Optimizing a COVID-19 Management Protocol in Pre-Existing Cardiovascular Disease Patients
![Thumbnail](/bitstream/handle/10576/33766/1-s2.0-S0146280622000743-main.pdf.jpg?sequence=4&isAllowed=y)
View/ Open
Publisher version (Check access options)
Check access options
Date
2022-03-25Author
Dina, AbushanabEldebs, Mohammed
Basha, Ahmed
Naseralallah, Lina
Kazkaz, Hadia
Moursi, Ahmed
Albazoon, Fatima
Wafi, Omar
Badran, Saif
Doi, Suhail A.R.
Al-Maadeed, Somaya
Alam, Mohammed Fasihul
Al-Badriyeh, Daoud
...show more authors ...show less authors
Metadata
Show full item recordAbstract
This study answers the question of whether the health care costs of managing COVID-19 in preexisting cardiovascular diseases (CVD) patients increased or decreased as a consequence of evidence-based efforts to optimize the initial COVID-19 management protocol in a CVD group of patients. A retrospective cohort study was conducted in preexisting CVD patients with COVID-19 in Hamad Medical Corporation, Qatar. From the health care perspective, only direct medical costs were considered, adjusted to their 2021 values. The impact of revising the protocol was a reduction in the overall costs in non-critically ill patients from QAR15,447 (USD 4243) to QAR4337 (USD 1191) per patient, with an economic benefit of QAR11,110 (USD 3051). In the critically ill patients, however, the cost increased from QAR202,094 (USD 55,505) to QAR292,856 (USD 80,433) per patient, with added cost of QAR90,762 (USD 24,928). Overall, regardless of critical care status, the optimization of the initial COVID-19 protocols in patients with preexisting CVD did not reduce overall health care costs, but increased it by QAR80,529 (USD 22,117) per patient.
Collections
- Computer Science & Engineering [2284 items ]
- COVID-19 Research [799 items ]
- Medicine Research [1382 items ]
- Pharmacy Research [1234 items ]
- Public Health [401 items ]